Presentation is loading. Please wait.

Presentation is loading. Please wait.

Ivana Jochmanova, Karel Pacak Genes selection and sample preparation for genome sequencing MGL User Group Meeting August 20th, 2014.

Similar presentations


Presentation on theme: "Ivana Jochmanova, Karel Pacak Genes selection and sample preparation for genome sequencing MGL User Group Meeting August 20th, 2014."— Presentation transcript:

1 Ivana Jochmanova, Karel Pacak Genes selection and sample preparation for genome sequencing MGL User Group Meeting August 20th, 2014

2 Outlines 1Pheochromocytoma/paraganglioma (PHEO/PGL) 2Gene selection for sequencing 3Backround and rationale for sample selection 4Sample preparation method

3 Pheochromocytoma/paraganglioma (PHEO/PGL) catecholamine producing tumors arising from sympathetic- or parasympathetic-associated chromaffin tissue. PGLs derived from chromaffin cells of adrenal medulla are called PHEOs.

4 Genetics of PHEO/PHL PHEO/PGL susceptibility genes Major: VHL, RET, NF1, SDHB and D Minor: TMEM127, SDHA and C, SDHAF2, MAX New genes: KIF1Bβ, PHD2, HIF2A, IDH, FH, H-RAS, K- RAS, BAP1 mutations in PHEO/PGL susceptibility genes affect HIF- α signaling pathway Gimenez-Roqueplo et al.: Horm Metab Res 2012; 44: Zhuang et al.: N Engl J Med 2012; 367: Jochmanova et al.: Physiol Res 2014; 63:S251-62

5 Invasion and metastasis Cell proliferation/(de)differentiation/ survival Glucose/energy metabolism Genomic instability Epithelial-mesenchymal transition Red blood cell production and iron metabolism HSP90 HRE p300 CPB HIF- α HIF- β Angiogenesis HIF target genes Jochmanova et al.: J Natl Canc Inst 2013; 105:

6 Summary of the pathways affecting HIF turnover involved in the development of various PGLs. TMEM127 MAX NF1 RET Jochmanova et al.: J Natl Canc Inst 2013; 105:

7 Selection of genes for sequencing Rationale for gene selection -in our research we are focusing on signaling pathways changed or disrupted in PHEO/PGL, especially HIF signaling pathway -selection of genes was done based on their involvement in the signaling pathways which were found to be altered in cancer, including PHEO/PGL -we also included genes already known to be mutated in patients whose samples were sequenced – this step was important to validate the sequencing data

8 Examples of genes selected for sequencing Genes known to be mutated in PHEO/PGL SDH-A, -B, -C, -D; SDHAF2, FH, VHL, NF1, RET, MAX, TMEM127, EGLN1, EPAS1 Genes involved in Krebs cycle: SDH-A,-B, -C,-D; FH; IDH; … Genes involved in MAPK signaling pathway: MAP2K1, -K2, -K4, MAP3K1 Genes involved in PI3K/AKT signaling pathway: PIK3CA, PIK3CG, PIK3R1, PIK3R2, AKT1, 2; PDK1, TSC1, 2 Genes involved in mTOR signaling pathway: EIF4E Genes involved in HIF signaling pathway: HIF1AN, HIF3A, EPAS1, VHL,…

9 Backround and rationale for sample selection 16 samples were selected: 8 genomic DNA samples (blood) 8 tumor DNA samples 10 samples were from patients with already known mutation associated with PHEO/PGL development (SDHB, SDHC, SDHD (2 samples), MAX, TMEM127, RET, and NF1 – these were selected to “validate” the sequencing accuracy 6 samples were from patients with not yet known mutations, thus to find out if sequencing will reveal any possibly new damaging mutations associated with PHEO/PGL

10 Sample preparation Blood and/or tumor tissue samples were obtained from patients after written consent. Blood sample preparation Isolation of DNA using commercial kit (Qiagen Dneasy Blood & Tissue Kit) Tissue DNA sample preparation Isolation of DNA using commercial kit (Qiagen Dneasy Blood & Tissue Kit)

11 THANK YOU FOR YOUR ATTENTION


Download ppt "Ivana Jochmanova, Karel Pacak Genes selection and sample preparation for genome sequencing MGL User Group Meeting August 20th, 2014."

Similar presentations


Ads by Google